Why It Matters
The infusion of capital accelerates Helex’s path to market for a high‑unmet‑need disease area, positioning the firm to capture value as the first mover in genetically‑targeted kidney treatments.
Deal Summary
NYC‑based therapeutics firm Helex announced a $3.5 million seed financing to advance its targeted medicines for genetic kidney diseases. The round was led by pi Ventures with participation from Bluehill Capital, SOSV and a broader syndicate of investors.
Comments
Want to join the conversation?
Loading comments...